Login / Signup

Real-world data on voxelotor to treat patients with sickle cell disease.

Kathryn MuschickTranaka FuquaCarrianne Stoker-PostierAlan R Anderson
Published in: European journal of haematology (2022)
Hematologic improvements were observed after voxelotor treatment, with a potential additive benefit with concomitant HU treatment.
Keyphrases
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • big data
  • patient reported outcomes
  • climate change
  • human health
  • smoking cessation